TRPV1 and skin disorder: In addition, a non-vanilloid TRPV1 antagonist, PAC-14028, has been shown to attenuate the inflammatory response and pruritus associated with dermatitis, as well as to prevent barrier damage and accelerate skin barrier recovery [36,37].